收入7.68亿元，净利润下降23.55%，翔宇医疗发布业绩快报

Core Viewpoint - The company reported a stable revenue growth of 3.26% in 2025, reaching 768 million yuan, but experienced a significant decline in net profit by 23.55%, indicating a divergence between revenue and profit due to cost structure issues [1][2]. Financial Performance - The total revenue for the reporting period was 768 million yuan, compared to 744 million yuan in the previous year, reflecting a growth of 3.26% [8]. - Operating profit decreased by 28.98% to 77 million yuan, while total profit fell by 30.25% to 74.79 million yuan [8]. - The net profit attributable to the parent company was 79 million yuan, down from 102 million yuan, marking a decline of 23.55% [8]. - The net profit after deducting non-recurring items dropped by 34.48%, indicating a more pronounced pressure on the core profitability [6][8]. - Basic earnings per share decreased by 22.73% to 0.51 yuan, and the weighted average return on equity fell by 1.32 percentage points to 3.70% [8]. Cost Structure and Profitability - The decline in profit is primarily attributed to increased research and development (R&D) expenses and higher depreciation and amortization costs [4][5]. - The company has been investing in high-end rehabilitation technology and talent, leading to a rise in overall expenses [4]. - As construction projects from previous investments come into operation, depreciation and amortization expenses have significantly increased, exerting continuous pressure on profits [5]. Asset and Equity Growth - As of the end of 2025, total assets reached 3.27 billion yuan, an increase of 11.64% year-on-year, while equity attributable to the parent company grew by 1.54% to 2.07 billion yuan [9]. - The growth in assets is primarily driven by ongoing construction and investment, indicating that the company is still in an expansion phase [9]. Cash Flow Analysis - The net operating cash flow was 178.59 million yuan, showing a decline compared to 2023 but remaining positive overall [10]. - Investment cash flow was negative at -275.76 million yuan, indicating continued investment efforts, while financing cash flow turned positive at 148.38 million yuan, providing funding support for expansion [16]. Strategic Outlook - The company is currently in a phase of "sustained investment and capability building," rather than a profit release phase [11]. - The rehabilitation medical equipment sector is driven by demographic trends and healthcare system development, suggesting strong long-term demand [12]. - The company is transitioning from "scale expansion" to "capability accumulation," with short-term performance fluctuations being a result of strategic investments [13]. Future Considerations - Key observation points include the ability to convert investments into product strength and market share, which will determine if the company can re-enter a profit release cycle [15].